Related Experiment Video
Updated: Mar 11, 2026

Design of an Open-Source, Low-Cost Bioink and Food Melt Extrusion 3D Printer
Published on: March 2, 2020
Social aspects in additive manufacturing of pharmaceutical products
Johanna Lind1, Sofia Kälvemark Sporrong1, Susanne Kaae1
1a Department of Pharmacy , University of Copenhagen , Copenhagen , Denmark.
Introduction:
Additive manufacturing (AM) techniques, such as drug printing, represent a new engineering approach that can implement the concept of personalized medicine via on-demand manufacturing of dosage forms with individually adjusted doses. Implementation of AM principles, such as pharmacoprinting, will challenge the entire drug distribution chain and affect the society at different levels. Areas covered: This work summarizes the concept of personalized medicine and gives an overview of possibilities for monitoring patients' health. The most recent activities in the field of printing technologies for fabrication of dosage forms and 'polypills' with flexible doses and tailored release profiles are reviewed. Different scenarios for the drug distribution chain with the required adjustments in drug logistics, quality systems and environmental safety are discussed, as well as whether AM will be used for production of on-demand medicine. The impact of such changes in the distribution chain on regulation, healthcare professionals and patients are highlighted. Expert opinion: Drug manufacturing by traditional methods is well-established, but it lacks the possibility for on-demand personalized drug production. With the recent approval of the first printed medicine, society should be prepared for the changes that will follow the introduction of printed pharmaceuticals.
Related Concept Videos
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

